Nasal vestibule squamous cell carcinoma: a population-based cohort study from DAHANCA

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Nasal vestibule squamous cell carcinoma : a population-based cohort study from DAHANCA. / Filtenborg, Mads V.; Lilja-Fischer, Jacob K.; Sharma, Maja B.; Primdahl, Hanne; Kjems, Julie; Plaschke, Christina C.; Charabi, Birgitte W.; Kristensen, Claus A.; Andersen, Maria; Andersen, Elo; Godballe, Christian; Johansen, Jørgen; Overgaard, Jens; Petersen, Kristian B.

I: Acta Oncologica, Bind 61, Nr. 2, 2022, s. 127-133.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Filtenborg, MV, Lilja-Fischer, JK, Sharma, MB, Primdahl, H, Kjems, J, Plaschke, CC, Charabi, BW, Kristensen, CA, Andersen, M, Andersen, E, Godballe, C, Johansen, J, Overgaard, J & Petersen, KB 2022, 'Nasal vestibule squamous cell carcinoma: a population-based cohort study from DAHANCA', Acta Oncologica, bind 61, nr. 2, s. 127-133. https://doi.org/10.1080/0284186X.2021.1994646

APA

Filtenborg, M. V., Lilja-Fischer, J. K., Sharma, M. B., Primdahl, H., Kjems, J., Plaschke, C. C., Charabi, B. W., Kristensen, C. A., Andersen, M., Andersen, E., Godballe, C., Johansen, J., Overgaard, J., & Petersen, K. B. (2022). Nasal vestibule squamous cell carcinoma: a population-based cohort study from DAHANCA. Acta Oncologica, 61(2), 127-133. https://doi.org/10.1080/0284186X.2021.1994646

Vancouver

Filtenborg MV, Lilja-Fischer JK, Sharma MB, Primdahl H, Kjems J, Plaschke CC o.a. Nasal vestibule squamous cell carcinoma: a population-based cohort study from DAHANCA. Acta Oncologica. 2022;61(2):127-133. https://doi.org/10.1080/0284186X.2021.1994646

Author

Filtenborg, Mads V. ; Lilja-Fischer, Jacob K. ; Sharma, Maja B. ; Primdahl, Hanne ; Kjems, Julie ; Plaschke, Christina C. ; Charabi, Birgitte W. ; Kristensen, Claus A. ; Andersen, Maria ; Andersen, Elo ; Godballe, Christian ; Johansen, Jørgen ; Overgaard, Jens ; Petersen, Kristian B. / Nasal vestibule squamous cell carcinoma : a population-based cohort study from DAHANCA. I: Acta Oncologica. 2022 ; Bind 61, Nr. 2. s. 127-133.

Bibtex

@article{da4dca98a90e47e98ec0ac68c7d16ac8,
title = "Nasal vestibule squamous cell carcinoma: a population-based cohort study from DAHANCA",
abstract = "Background: Cancer of the nasal vestibule is a rare type of malignancy dominated by squamous cell carcinoma (SCC), and with poor survival. The treatment is either radiotherapy, surgery or a combination of both. Previous studies have shown a 5-year disease-specific survival of 74% and overall survival (OS) of 50%. Our objective was to describe the consecutive cohort of patients diagnosed with SCC of the nasal vestibule in Denmark from 2008 until 2018 and evaluate prognostic factors and treatment outcome using locoregional failure (LRF), disease-specific mortality (DSM), and OS as endpoints. Methods: All patients diagnosed with SCC of the nasal vestibule from 2008 until 2018 were identified in the nationwide clinical database, DAHANCA and were followed for LRF and death (DSM and OS) until March 2021. OS was analysed using Kaplan–Meier estimator, and cumulative incidence of LRF and DSM were analysed using the Aalen–Johansen estimator. Analysis of prognostic factors was performed using Cox proportional hazard models. Results: A total of 162 patients were identified. The median age was 71 years and 54% were male. Disease stage at the time of diagnosis were stage I (70%), II (17%), III (2%) and IV (11%). Curatively intended treatment was performed in 146 patients (90%), of which treatment failure occurred in 42 patients (29%). Most failures occurred at the primary tumour site (64%). Cancer Patient Pathways recommended time to treatment was fulfilled in 71% of patients. The 5-year OS and DSM in patients treated with curative intent were 65% and 11%, respectively. Stage was a significant independent prognostic factor. No difference in LRF, DSM or OS were shown between the applied treatments. Conclusions: Stage is the main independent prognostic factor, and failure most commonly appear at the primary tumour site.",
keywords = "Nasal vestibule cancer, national population study, squamous cell carcinoma, survival, treatment outcome",
author = "Filtenborg, {Mads V.} and Lilja-Fischer, {Jacob K.} and Sharma, {Maja B.} and Hanne Primdahl and Julie Kjems and Plaschke, {Christina C.} and Charabi, {Birgitte W.} and Kristensen, {Claus A.} and Maria Andersen and Elo Andersen and Christian Godballe and J{\o}rgen Johansen and Jens Overgaard and Petersen, {Kristian B.}",
note = "Publisher Copyright: {\textcopyright} 2021 Acta Oncologica Foundation.; 20th Acta Oncologica Symposium : BiGART 2021 - Biology-Guided Adaptive Radiotherapy ; Conference date: 05-10-2021 Through 06-10-2021",
year = "2022",
doi = "10.1080/0284186X.2021.1994646",
language = "English",
volume = "61",
pages = "127--133",
journal = "Acta Oncologica",
issn = "1100-1704",
publisher = "Taylor & Francis",
number = "2",

}

RIS

TY - JOUR

T1 - Nasal vestibule squamous cell carcinoma

T2 - 20th Acta Oncologica Symposium

AU - Filtenborg, Mads V.

AU - Lilja-Fischer, Jacob K.

AU - Sharma, Maja B.

AU - Primdahl, Hanne

AU - Kjems, Julie

AU - Plaschke, Christina C.

AU - Charabi, Birgitte W.

AU - Kristensen, Claus A.

AU - Andersen, Maria

AU - Andersen, Elo

AU - Godballe, Christian

AU - Johansen, Jørgen

AU - Overgaard, Jens

AU - Petersen, Kristian B.

N1 - Publisher Copyright: © 2021 Acta Oncologica Foundation.

PY - 2022

Y1 - 2022

N2 - Background: Cancer of the nasal vestibule is a rare type of malignancy dominated by squamous cell carcinoma (SCC), and with poor survival. The treatment is either radiotherapy, surgery or a combination of both. Previous studies have shown a 5-year disease-specific survival of 74% and overall survival (OS) of 50%. Our objective was to describe the consecutive cohort of patients diagnosed with SCC of the nasal vestibule in Denmark from 2008 until 2018 and evaluate prognostic factors and treatment outcome using locoregional failure (LRF), disease-specific mortality (DSM), and OS as endpoints. Methods: All patients diagnosed with SCC of the nasal vestibule from 2008 until 2018 were identified in the nationwide clinical database, DAHANCA and were followed for LRF and death (DSM and OS) until March 2021. OS was analysed using Kaplan–Meier estimator, and cumulative incidence of LRF and DSM were analysed using the Aalen–Johansen estimator. Analysis of prognostic factors was performed using Cox proportional hazard models. Results: A total of 162 patients were identified. The median age was 71 years and 54% were male. Disease stage at the time of diagnosis were stage I (70%), II (17%), III (2%) and IV (11%). Curatively intended treatment was performed in 146 patients (90%), of which treatment failure occurred in 42 patients (29%). Most failures occurred at the primary tumour site (64%). Cancer Patient Pathways recommended time to treatment was fulfilled in 71% of patients. The 5-year OS and DSM in patients treated with curative intent were 65% and 11%, respectively. Stage was a significant independent prognostic factor. No difference in LRF, DSM or OS were shown between the applied treatments. Conclusions: Stage is the main independent prognostic factor, and failure most commonly appear at the primary tumour site.

AB - Background: Cancer of the nasal vestibule is a rare type of malignancy dominated by squamous cell carcinoma (SCC), and with poor survival. The treatment is either radiotherapy, surgery or a combination of both. Previous studies have shown a 5-year disease-specific survival of 74% and overall survival (OS) of 50%. Our objective was to describe the consecutive cohort of patients diagnosed with SCC of the nasal vestibule in Denmark from 2008 until 2018 and evaluate prognostic factors and treatment outcome using locoregional failure (LRF), disease-specific mortality (DSM), and OS as endpoints. Methods: All patients diagnosed with SCC of the nasal vestibule from 2008 until 2018 were identified in the nationwide clinical database, DAHANCA and were followed for LRF and death (DSM and OS) until March 2021. OS was analysed using Kaplan–Meier estimator, and cumulative incidence of LRF and DSM were analysed using the Aalen–Johansen estimator. Analysis of prognostic factors was performed using Cox proportional hazard models. Results: A total of 162 patients were identified. The median age was 71 years and 54% were male. Disease stage at the time of diagnosis were stage I (70%), II (17%), III (2%) and IV (11%). Curatively intended treatment was performed in 146 patients (90%), of which treatment failure occurred in 42 patients (29%). Most failures occurred at the primary tumour site (64%). Cancer Patient Pathways recommended time to treatment was fulfilled in 71% of patients. The 5-year OS and DSM in patients treated with curative intent were 65% and 11%, respectively. Stage was a significant independent prognostic factor. No difference in LRF, DSM or OS were shown between the applied treatments. Conclusions: Stage is the main independent prognostic factor, and failure most commonly appear at the primary tumour site.

KW - Nasal vestibule cancer

KW - national population study

KW - squamous cell carcinoma

KW - survival

KW - treatment outcome

U2 - 10.1080/0284186X.2021.1994646

DO - 10.1080/0284186X.2021.1994646

M3 - Journal article

C2 - 34709956

AN - SCOPUS:85118345370

VL - 61

SP - 127

EP - 133

JO - Acta Oncologica

JF - Acta Oncologica

SN - 1100-1704

IS - 2

Y2 - 5 October 2021 through 6 October 2021

ER -

ID: 312760615